LTRN Stock Analysis: Buy, Sell, or Hold?
LTRN - Lantern Pharma Inc. Common Stock
$3.97
0.14 (3.66%)
▲
5d:
+1.53%
30d:
+13.43%
90d:
+78.03%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 12, 2026
Get Alerted When LTRN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: LTRN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: LTRN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: LTRN is currently trading at $3.97, which is considered extended relative to its 30-day fair value range of $3.35 to $3.91.
Technical Outlook: Technically, LTRN is showing sideways momentum. Immediate support is located at $3.16, while resistance sits at $4.20. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $20.00 (+422.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, LTRN is showing sideways momentum. Immediate support is located at $3.16, while resistance sits at $4.20. The stock is showing strong short-term momentum, up 3.7% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $20.00 (+422.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.35 -
$3.91
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
65.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.7%)
- BULLISH: Trading 422.2% below Wall St target ($20.00)
Trading Range Analysis
30-Day Trading Range
$3.35 -
$3.91
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$0.79
(19.9%)
Support & Resistance Levels
Support Level
$3.16
Resistance Level
$4.20
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.90
Wall Street Target
$20.00
(+422.2%)
Share & Embed Analysis
Last updated: June 24, 2026 11:09 AM ET
Data refreshes hourly during market hours. Next update: 12:09 PM
Data refreshes hourly during market hours. Next update: 12:09 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LTRN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 54 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 62 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 55 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$38 | 62 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 57 HOLD |
